Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
Am J Clin Pathol ; 161(1): 83-88, 2024 Jan 04.
Article in English | MEDLINE | ID: mdl-37698998

ABSTRACT

OBJECTIVES: Critical hyperbilirubinemia in preterm neonates, a condition requiring greater attention, is treated with phototherapy or exchange transfusion when bilirubin results exceed gestational age and age-specific medical decision levels (MDLs) to prevent bilirubin-induced neurologic damage. Conventional evaluation involves multiple manual steps and is poised to inconsistencies and delays. METHODS: We designed and implemented an electronic clinical decision support (CDS) tool to identify and alert neonatal intensive care unit clinicians of critical hyperbilirubinemia with a SmartZone alert. We evaluated the performance of our manual evaluation workflow, the accuracy of the electronic CDS tool, and the outcome of the electronic CDS tool to reduce the time to place orders for interventions. RESULTS: Among the 22 patients who met the criteria to have phototherapy ordered before implementing the electronic CDS tool, 20 (90%) had phototherapy ordered. Fourteen (70%) phototherapy orders were placed less than 24 hours, 4 phototherapy orders were placed 24 to 72 hours, and 2 orders were placed more than 72 hours after bilirubin results exceeded the corresponding MDLs. Among the 15 patients who met the criteria to have phototherapy ordered after implementing the electronic CDS tool, all (100%) received phototherapy orders, with 14 (93%) placed less than 24 hours and 1 order placed less than 48 hours. The electronic CDS tool identified all eligible patients correctly. The proportion of phototherapy ordered less than 24 hours increased from 70% to 93% after the implementation of the electronic CDS tool. CONCLUSIONS: The electronic CDS tool promoted more appropriate and timely intervention orders to manage critical hyperbilirubinemia in preterm neonates.


Subject(s)
Decision Support Systems, Clinical , Hyperbilirubinemia, Neonatal , Infant, Newborn , Humans , Pregnancy , Female , Gestational Age , Hyperbilirubinemia, Neonatal/therapy , Bilirubin , Phototherapy/methods
2.
J Virol ; 95(22): e0096621, 2021 10 27.
Article in English | MEDLINE | ID: mdl-34495700

ABSTRACT

The high pathogenicity of SARS-CoV-2 requires it to be handled under biosafety level 3 conditions. Consequently, Spike protein-pseudotyped vectors are a useful tool to study viral entry and its inhibition, with retroviral, lentiviral (LV), and vesicular stomatitis virus (VSV) vectors the most commonly used systems. Methods to increase the titer of such vectors commonly include concentration by ultracentrifugation and truncation of the Spike protein cytoplasmic tail. However, limited studies have examined whether such a modification also impacts the protein's function. Here, we optimized concentration methods for SARS-CoV-2 Spike-pseudotyped VSV vectors, finding that tangential flow filtration produced vectors with more consistent titers than ultracentrifugation. We also examined the impact of Spike tail truncation on transduction of various cell types and sensitivity to convalescent serum neutralization. We found that tail truncation increased Spike incorporation into both LV and VSV vectors and resulted in enhanced titers but had no impact on sensitivity to convalescent serum. In addition, we analyzed the effect of the D614G mutation, which became a dominant SARS-CoV-2 variant early in the pandemic. Our studies revealed that, similar to the tail truncation, D614G independently increases Spike incorporation and vector titers, but this effect is masked by also including the cytoplasmic tail truncation. Therefore, the use of full-length Spike protein, combined with tangential flow filtration, is recommended as a method to generate high titer pseudotyped vectors that retain native Spike protein functions. IMPORTANCE Pseudotyped viral vectors are useful tools to study the properties of viral fusion proteins, especially those from highly pathogenic viruses. The Spike protein of SARS-CoV-2 has been investigated using pseudotyped lentiviral and VSV vector systems, where truncation of its cytoplasmic tail is commonly used to enhance Spike incorporation into vectors and to increase the titers of the resulting vectors. However, our studies have shown that such effects can also mask the phenotype of the D614G mutation in the ectodomain of the protein, which was a dominant variant arising early in the COVID-19 pandemic. To better ensure the authenticity of Spike protein phenotypes when using pseudotyped vectors, we recommend using full-length Spike proteins, combined with tangential flow filtration methods of concentration if higher-titer vectors are required.


Subject(s)
Genetic Vectors/physiology , SARS-CoV-2/genetics , Spike Glycoprotein, Coronavirus/genetics , Animals , Antibodies, Neutralizing/immunology , Cell Line , Genetic Vectors/genetics , Genetic Vectors/immunology , Humans , Lentivirus/genetics , Mutation , SARS-CoV-2/immunology , Spike Glycoprotein, Coronavirus/immunology , Vesicular stomatitis Indiana virus/genetics , Viral Load/genetics
4.
Leukemia ; 34(7): 1741-1750, 2020 07.
Article in English | MEDLINE | ID: mdl-32060402

ABSTRACT

The rarity of mixed phenotype acute leukemia (MPAL) has precluded adequate data to incorporate minimal residual disease (MRD) monitoring into therapy. Fluidity in MPAL classification systems further complicates understanding its biology and outcomes; this includes uncertainty surrounding the impact of shifting diagnostic requirements even between iterations of the World Health Organization (WHO) classification. Our primary objective was to address these knowledge gaps. To do so, we analyzed clinicopathologic features, therapy, MRD, and survival in a centrally-reviewed, multicenter cohort of MPAL uniformly diagnosed by the WHO classification and treated with acute lymphoblastic leukemia (ALL) regimens. ALL induction therapy achieved an EOI MRD negative (<0.01%) remission in most patients (70%). EOI MRD positivity was predictive of 5-year EFS (HR = 6.00, p < 0.001) and OS (HR = 9.57, p = 0.003). Patients who cleared MRD by EOC had worse survival compared with those EOI MRD negative. In contrast to adults with MPAL, ALL therapy without transplantation was adequate to treat most pediatric patients. Earlier MRD clearance was associated with better treatment success and survival. Prospective trials are now necessary to validate and refine MRD thresholds within the pediatric MPAL population and to identify salvage strategies for those with poor predicted survival.


Subject(s)
Hematopoietic Stem Cell Transplantation/mortality , Induction Chemotherapy/mortality , Leukemia/mortality , Neoplasm, Residual/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Child , Cohort Studies , Female , Follow-Up Studies , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Leukemia/classification , Leukemia/pathology , Leukemia/therapy , Male , Neoplasm, Residual/epidemiology , Neoplasm, Residual/pathology , Phenotype , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Prognosis , Survival Rate , United States/epidemiology
7.
Pediatr Blood Cancer ; 65(9): e27265, 2018 09.
Article in English | MEDLINE | ID: mdl-29797659

ABSTRACT

A pediatric patient diagnosed initially with B-lymphoblastic leukemia (B-ALL) relapsed with lineage switch to acute myeloid leukemia (AML) after chimeric antigen receptor T-cell (CAR-T) therapy and hematopoietic stem cell transplant. A TCF3-ZNF384 fusion was identified at diagnosis, persisted through B-ALL relapse, and was also present in the AML relapse cell population. ZNF384-rearrangements define a molecular subtype of B-ALL characterized by a pro-B-cell immunophenotype; furthermore, ZNF384-rearrangements are prevalent in mixed-phenotype acute leukemias. Lineage switch following CAR-T therapy has been described in patients with KMT2A (mixed lineage leukemia) rearrangements, but not previously in any patient with ZNF384 fusion.


Subject(s)
Immunotherapy, Adoptive/methods , Leukemia, Myeloid, Acute/etiology , Myeloid Cells/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Receptors, Chimeric Antigen/immunology , T-Lymphocyte Subsets/immunology , Basic Helix-Loop-Helix Transcription Factors/genetics , Cell Lineage , Combined Modality Therapy , Cord Blood Stem Cell Transplantation , Fatal Outcome , Hematopoietic Stem Cell Transplantation , Humans , Infant , Leukemia, Myeloid, Acute/genetics , Male , Oncogene Proteins, Fusion/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Salvage Therapy , Trans-Activators/genetics
9.
Methods Mol Biol ; 1678: 321-345, 2018.
Article in English | MEDLINE | ID: mdl-29071685

ABSTRACT

Inborn errors of immunity are the cause of the primary immunodeficiency diseases, an extremely diverse group of genetic defects that are inherited in Mendelian fashion and result in the impairment of development and/or function of key components of the immune system. Since the last publication of this chapter in 2011, there have been approximately 100 new primary immunodeficiency diseases officially classified by the "Expert Committee for Primary Immunodeficiency" who met in 2015 and the numbers will continue to rise with the continued evolution and widespread adoption of genomic technologies. The ultimate diagnostic modality involves the identification of a mutation in a gene whose product is known to be involved in immunity. DNA sequencing is however still a rather time-consuming technology. Flow cytometry applications have evolved that are rapid, specific, and relatively inexpensive to screen for abnormalities associated with primary immunodeficiency diseases. The numerous flow cytometry procedures that have been developed to detect abnormalities in peripheral blood cells of primary immunodeficiency patients can barely be covered in an entire book, let alone one chapter. Instead of attempting to cover each disease with a specific assay or test, we will review four procedures each covering one of the three following broad forms of immune abnormalities observed in primary immunodeficiency, i.e., immune subset abnormalities, immune marker abnormalities, and immune function abnormalities.


Subject(s)
Flow Cytometry , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/metabolism , Antigens, Surface/metabolism , Biomarkers , CD40 Ligand/metabolism , Data Interpretation, Statistical , Flow Cytometry/methods , Humans , Immunologic Deficiency Syndromes/etiology , Immunophenotyping , Lymphocyte Subsets/immunology , Lymphocyte Subsets/metabolism , Quality Control , Reference Values , Respiratory Burst , Software
10.
Sci Rep ; 7: 45932, 2017 04 05.
Article in English | MEDLINE | ID: mdl-28378832

ABSTRACT

Hepatoblastoma (HB) is the most common primary liver cancer in children. The conventional serum marker for HB, alpha-fetoprotein (AFP), has its limitations. Novel serum markers need to be explored. Glypican 3 (GPC3) has been reported to be an excellent histological immunomarker for HB. However, the clinical value of serum GPC3 in patients with HB is unknown. A total of 184 serum samples were tested for both GPC3 by ELISA, and AFP by immunometric assay. Of these, 134 were from 32 patients with HB at three treatment stages, 30 from age-matched patients with benign hepatobiliary disorders (BHD) and 20 from age-matched "normal controls"(NC). We found that the GPC3 levels in HB pretreatment group were significantly higher than those in NC group and HB remission group but not statistically different from those in BHD group and HB during treatment group. In contrast, AFP showed significant differences among different groups. The areas under the receiver operating curve (AUROC) value, sensitivity and specificity of GPC3 for HB pretreatment group versus all controls were all significantly lower than those of AFP. Serum GPC3 levels were not associated with prognostic parameters. We concluded that GPC3 is inferior to AFP as a serum marker for HB.


Subject(s)
Biomarkers, Tumor/blood , Glypicans/blood , Hepatoblastoma/blood , Liver Neoplasms/blood , Adolescent , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , Hepatoblastoma/diagnosis , Humans , Infant , Liver Neoplasms/diagnosis , Male , Prognosis , ROC Curve , alpha-Fetoproteins/analysis
11.
Am J Clin Pathol ; 147(4): 374-381, 2017 04 01.
Article in English | MEDLINE | ID: mdl-28340210

ABSTRACT

Objectives: Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) requires immunophenotypic evidence of B-lineage and absence of specific myeloid or T-lineage markers. Rare cases of otherwise typical B-ALL express myeloperoxidase (MPO) detectable by flow cytometry with an absence of other myeloid markers, but the clinical significance of this finding is not well studied. Methods: A retrospective cohort analysis of flow cytometry and clinical data was performed to investigate the clinical outcome of this specific group of patients. Results: Twenty-nine cases of otherwise typical B-ALL that expressed MPO by flow cytometry (B-ALL-isoMPO) without expression of other myeloid markers were identified. The B-ALL-isoMPO group had a significantly increased incidence of relapse (univariate log rank P = .0083; multivariate hazard ratio, 2.50; 95% confidence interval, 1.07-5.85; P = .034) and significantly worse event-free survival by univariate analysis (log rank P = .0066) compared with a reference group of patients with B-ALL from the same time period (n = 264). Conclusions: To our knowledge, this is the first report to document the clinical outcomes in a group of pediatric patients with B-ALL that expresses MPO in the absence of other myeloid markers. This group had an increased rate of relapse and a worse event-free survival than the patients with B-ALL who did not express MPO.


Subject(s)
Biomarkers, Tumor/metabolism , Leukemia, B-Cell/diagnosis , Peroxidase/metabolism , Adolescent , B-Lymphocytes/metabolism , Child , Child, Preschool , Cohort Studies , Disease-Free Survival , Female , Flow Cytometry , Humans , Immunophenotyping , Infant , Isoenzymes/metabolism , Kaplan-Meier Estimate , Leukemia, B-Cell/metabolism , Male , Recurrence , Retrospective Studies , Risk
12.
BMC Pediatr ; 16: 54, 2016 04 26.
Article in English | MEDLINE | ID: mdl-27118537

ABSTRACT

BACKGROUND: While biomarkers for chronic fatigue syndrome (CFS) are beginning to emerge they typically require a highly specialized clinical laboratory. We hypothesized that subsets of commonly measured laboratory markers used in combination could support the diagnosis of post-infectious CFS (PI-CFS) in adolescents following infectious mononucleosis (IM) and help determine who might develop persistence of symptoms. METHODS: Routine clinical laboratory markers were collected prospectively in 301 mono-spot positive adolescents, 4 % of whom developed CFS (n = 13). At 6, 12, and 24 months post-diagnosis with IM, 59 standard tests were performed including metabolic profiling, liver enzyme panel, hormone profiles, complete blood count (CBC), differential white blood count (WBC), salivary cortisol, and urinalysis. Classification models separating PI-CFS from controls were constructed at each time point using stepwise subset selection. RESULTS: Lower ACTH levels at 6 months post-IM diagnosis were highly predictive of CFS (AUC p = 0.02). ACTH levels in CFS overlapped with healthy controls at 12 months, but again showed a trend towards a deficiency at 24 months. Conversely, estradiol levels depart significantly from normal at 12 months only to recover at 24 months (AUC p = 0.02). Finally, relative neutrophil count showed a significant departure from normal at 24 months in CFS (AUC p = 0.01). Expression of these markers evolved differently over time between groups. CONCLUSIONS: Preliminary results suggest that serial assessment of stress and sex hormones as well as the relative proportion of innate immune cells measured using standard clinical laboratory tests may support the diagnosis of PI-CFS in adolescents with IM.


Subject(s)
Biomarkers/metabolism , Fatigue Syndrome, Chronic/diagnosis , Infectious Mononucleosis/complications , Adolescent , Blood Cell Count , Case-Control Studies , Child , Fatigue Syndrome, Chronic/etiology , Fatigue Syndrome, Chronic/metabolism , Female , Follow-Up Studies , Humans , Linear Models , Male , Prospective Studies
13.
J Immunol Methods ; 423: 1-2, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26229043
14.
Am J Clin Pathol ; 142(4): 437-44, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25239409

ABSTRACT

OBJECTIVES: Clinical laboratory immunology affects practically every aspect of medicine. Accordingly, appropriately trained, board-certified clinical laboratory immunologists are key contributors to the diagnosis and management of patients with various immune-mediated conditions. This review highlights the availability of postdoctoral level training programs for clinical laboratory immunology and identifies possible career tracks. METHODS: Fundamental elements for doctoral level clinical laboratory immunologists are identified and the critical components of diagnostic immunology training as well as career opportunities in and out of academia are described. RESULTS: Relative to other disciplines in laboratory medicine, little emphasis has been given to clinical laboratory immunology in medical, graduate, and postgraduate training. Formal postgraduate fellowship programs and board certification examinations are available, yet there remains a significant lack of awareness in the medical education community about the value and necessity of training in this field. CONCLUSIONS: It is anticipated that sharing this knowledge will increase awareness of the discipline of clinical laboratory immunology at the postdoctoral level with implications for the practice of laboratory medicine.


Subject(s)
Allergy and Immunology/education , Certification , Education, Medical, Graduate , Laboratories , Medical Laboratory Science/education , Clinical Laboratory Services/standards , Curriculum , Humans , Immunologic Techniques
15.
J Clin Immunol ; 34(6): 677-80, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24789686

ABSTRACT

Major histocompatibility complex class II (MHCII) deficiency represents a rare form of severe immunodeficiency associated with increased susceptibility to viral, bacterial, and fungal pathogens and commonly leads to failure to thrive and early death. This autosomal recessive disorder is caused by mutations in MHCII transcription regulator genes, resulting in impaired expression of MHCII, and it is usually seen in consanguineous populations. Our patient presented at age 15 months with a history of developmental delay, multiple respiratory infections and skin abscesses, and recently, at 5 years of age, he was found to have disseminated Mycobacterium avium complex. His mother is Mexican-American, and his father is Persian. Laboratory investigations showed hypogammaglobulinemia, modest T-lymphopenia, borderline mitogen responses, absent tetanus toxoid and candida antigen lymphoproliferative assays, and absent tetanus toxoid and Haemophilus influenzae type b antibody levels. Flow cytometry demonstrated absent HLA-DR antigen on monocytes and B-cells, and a diagnosis of MHCII deficiency was made. Genetic analysis yielded a homozygous pathogenic class II transactivator (CIITA) mutation. The same mutation was found in both parents. Coincidently, an Xq28 microduplication was identified and likely was the cause of the patient's developmental delay. This patient demonstrated some of the typical features of MHCII deficiency with the addition of several unique findings: disseminated M. avium complex, homozygosity in a CIITA mutation despite remarkably diverse parental ethnicity, and coincident Xq28 microdeletion with mild intellectual disability.


Subject(s)
B-Lymphocytes/immunology , Chromosomes, Human, X/genetics , Developmental Disabilities/diagnosis , HLA-DR Antigens/metabolism , Immunologic Deficiency Syndromes/diagnosis , Monocytes/immunology , Mycobacterium avium Complex/physiology , Mycobacterium avium-intracellulare Infection/diagnosis , Nuclear Proteins/genetics , Sequence Deletion/genetics , Trans-Activators/genetics , Adolescent , Child, Preschool , DNA Mutational Analysis , Developmental Disabilities/genetics , Ethnicity , HLA-DR Antigens/genetics , Homozygote , Humans , Immunologic Deficiency Syndromes/genetics , Male , Mexican Americans , Mycobacterium avium-intracellulare Infection/genetics , Parents , Pedigree
16.
J Transl Med ; 10: 191, 2012 Sep 13.
Article in English | MEDLINE | ID: mdl-22973830

ABSTRACT

BACKGROUND: As Chronic Fatigue Syndrome (CFS) has been known to follow Epstein-Bar virus (EBV) and other systemic infections; our objective was to describe differences in immune activation in post-infective CFS (PI-CFS) patients and recovered controls. We studied 301 adolescents prospectively over 24 months following the diagnosis of monospot-positive infectious mononucleosis (IM). We found an incidence of CFS at 6, 12 and 24 months of 13%, 7% and 4% respectively. METHODS: Using chemiluminescent imaging we measured the concentrations of IL-1a, 1b, 2, 4, 5, 6, 8, 10, 12 (p70), 13, 15, 17 and 23, IFN-γ, TNF-α and TNF-ß in duplicate plasma samples available in bio-bank from 9 PI-CFS subjects and 12 recovered controls at 24 months post-infection. RESULTS: Standard comparative analysis indicated significant differences in IL-8 and 23 across subject groups. In constructing a linear classification model IL-6, 8 and 23 were selected by two different statistical approaches as discriminating features, with IL-1a, IL-2 and IFN-γ also selected in one model or the other. This supported an assignment accuracy of better than 80% at a confidence level of 0.95 into PI-CFS versus recovered controls. CONCLUSION: These results suggest that co-expression patterns in as few as 5 cytokines associated with Th17 function may hold promise as a tool for the diagnosis of post-infectious CFS.


Subject(s)
Cytokines/genetics , Fatigue/immunology , Gene Expression Profiling , Infectious Mononucleosis/immunology , Adolescent , Cohort Studies , Fatigue/genetics , Humans , Infectious Mononucleosis/genetics
17.
Allergy Asthma Proc ; 33 Suppl 1: 108-111, 2012.
Article in English | MEDLINE | ID: mdl-22794704

ABSTRACT

Allergen-specific IgE antibody is the most commonly ordered in vitro test in the practice of allergy and is used to diagnose type I hypersensitivity reactions to foods or reactivity to aeroallergens in patients with relative contraindications to skin-prick testing such as dermatographism. The Phadebas radioallergosorbent test (RAST; Pharmacia, Uppsala, Sweden) was the first assay reported for the detection of the allergen-specific IgE antibody. In a RAST, antigen (allergen) is bound to a solid phase, such as a paper disk, and then incubated with human serum. A buffer wash removes unbound serum proteins, and radiolabeled anti-human IgE is added to detect bound IgE, if present. The results are reported in arbitrary units of IgE per milliliter of serum. The term RAST was originally a brand name but it is now often used colloquially (and incorrectly) to describe any in vitro assay for allergen-specific IgE. Total serum IgE can be measured and is helpful in determining atopic presentations such as in allergic bronchopulmonary aspergillosis or in patients with persistent asthma who are candidates for monoclonal anti-IgE antibody therapy with, omalizumab. In patients with recurrent bacterial infections of the sinopulmonary tract, the basic humoral immune system testing includes measuring quantitative immunoglobulins (IgG, IgA, and IgM) and comparing them to age-matched normal ranges. Most clinical laboratories use nephelometry to measure immunoglobulin levels quantitatively. Nephelometry detects either the rate or the end point of soluble immune complex formation (the IgG in sera complexes with an anti-IgG antibody forming a classic immunoprecipitation reaction) by monitoring the scatter of transmitted light. The most common method for the screening of cellular immunodeficiency involved the measurement of the absolute and relative representation of the major lymphocyte subsets, T-cells, T-helper cells, T-cytotoxic cells, B-cells and NK-cells.


Subject(s)
Hypersensitivity/diagnosis , Immune System Diseases/diagnosis , Immunologic Tests/methods , Humans , Hypersensitivity/immunology , Immune System Diseases/immunology
18.
Hum Immunol ; 72(5): 392-7, 2011 May.
Article in English | MEDLINE | ID: mdl-21315129

ABSTRACT

This is an observational study with the primary objective to measure donor-specific immune responses by pediatric liver transplant (LT) recipients, using cell surface expression of lymphocyte activation markers and cytokine secretion in mixed lymphocyte reactions. The secondary objective was to demonstrate possible mechanism(s) involved in those who demonstrated donor-specific hyporesponsiveness. Study participants included 17 recipients, their respective parental donors, the non-donor parent, as well as unrelated third party individuals. Within the CD4(+) population, two distinct patterns of CD69 and CD71 expressions were observed: recipients who had a lower percentage of CD4(+)CD69(+) and CD4(+)CD71(+) cells after donor versus non-donor stimulation (therefore a donor/non-donor ratio <1); and recipients who had a higher percentage of CD4(+)CD69(+) and CD4(+)CD71(+) cells after donor versus non-donor stimulation (therefore a donor/non-donor ratio ≥1). Eight recipients had the above defined ratio of <1, with significantly decreased interferon-γ secretion after donor versus non-donor stimulation. CD4(+)CD25(hi.)CD127- regulatory T cells from these eight recipients suppressed donor and non-donor cell induced proliferation. Suppression of proliferation was partially abrogated by interleukin-2. In conclusion, CD69 and CD71 cell surface expression with interferon-γ secretion can be used to identify two distinct populations in pediatric LT recipients. Both active regulation and anergy underlie donor specific hyporesponsiveness.


Subject(s)
Graft Rejection/diagnosis , Graft Rejection/immunology , Liver Transplantation , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Regulatory/metabolism , Antigens, CD/metabolism , Biomarkers/metabolism , Cells, Cultured , Child , Humans , Immunophenotyping , Interferon-gamma/metabolism , Isoantigens/immunology , Living Donors , Lymphocyte Activation , Lymphocyte Culture Test, Mixed , Pediatrics , Prognosis , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/pathology , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/pathology , Transplantation Tolerance
19.
Clin Vaccine Immunol ; 18(4): 609-14, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21270283

ABSTRACT

The objective of this study was to retrospectively evaluate the utility of serum neopterin as a diagnostic marker of hemophagocytic lymphohistiocytosis (HLH). The medical records of patients diagnosed with HLH (familial and secondary) between January 2000 and May 2009 were reviewed retrospectively, and clinical and laboratory information related to HLH criteria, in addition to neopterin levels, was recorded. A group of 50 patients with active juvenile dermatomyositis (JDM) (who routinely have neopterin levels assessed) served as controls for the assessment of the accuracy, sensitivity, and specificity of neopterin as a diagnostic test for HLH. The Pearson correlation was used to measure the association between serum neopterin levels and established HLH-related laboratory data. Serum neopterin levels were measured using a competitive enzyme immunoassay. During the time frame of the study, 3 patients with familial HLH and 18 patients with secondary HLH were identified as having had serum neopterin measured (all HLH patients were grouped together). The mean neopterin levels were 84.9 nmol/liter (standard deviation [SD], 83.4 nmol/liter) for patients with HLH and 21.5 nmol/liter (SD, 10.13 nmol/liter) for patients with JDM. A cutoff value of 38.9 nmol/liter was 70% sensitive and 95% specific for HLH. For HLH patients, neopterin levels correlated significantly with ferritin levels (r = 0.76, P = 0.0007). In comparison to the level in a control group of JDM patients, elevated serum neopterin was a sensitive and specific marker for HLH. Serum neopterin has value as a diagnostic marker of HLH, and prospective studies are under way to further evaluate its role as a marker for early diagnosis and management of patients.


Subject(s)
Biomarkers/blood , Lymphohistiocytosis, Hemophagocytic/diagnosis , Neopterin/blood , Adolescent , Child , Child, Preschool , Female , Humans , Immunoassay/methods , Infant , Male , Retrospective Studies , Sensitivity and Specificity , Serum/chemistry
20.
Methods Mol Biol ; 699: 317-35, 2011.
Article in English | MEDLINE | ID: mdl-21116990

ABSTRACT

The primary immunodeficiency diseases (PIDs) encompass an extremely large and diverse number of clinical disorders caused by mutations in genes that affect virtually every measurable component of our immune systems. Many of the genetic mutations lead to abnormalities that can be detected in circulating peripheral blood cells of suspected patients by flow cytometry and the appropriate combinations of reagents and in vitro manipulations. The flow cytometry procedures that have been developed to detect abnormalities in peripheral blood cells of primary immunodeficiency patients can barely be covered in an entire book, let alone one chapter. Instead of attempting to cover each disease with a specific assay or test, we review three procedures each covering a global aspect of the observed immune abnormality, i.e., detection of lymphocyte subset abnormalities, lymphocyte "marker" abnormalities, and leukocyte function abnormalities.


Subject(s)
Flow Cytometry , Immunologic Deficiency Syndromes/diagnosis , Immunophenotyping/methods , CD40 Ligand/metabolism , Clinical Laboratory Techniques , Data Collection , Granulomatous Disease, Chronic/diagnosis , Granulomatous Disease, Chronic/immunology , Humans , Hyper-IgM Immunodeficiency Syndrome, Type 1/diagnosis , Hyper-IgM Immunodeficiency Syndrome, Type 1/immunology , Immunologic Deficiency Syndromes/immunology , Lymphocyte Subsets/immunology , Lymphocyte Subsets/metabolism , Quality Control , Respiratory Burst
SELECTION OF CITATIONS
SEARCH DETAIL
...